JPWO2023210740A5 - - Google Patents
Info
- Publication number
- JPWO2023210740A5 JPWO2023210740A5 JP2024518024A JP2024518024A JPWO2023210740A5 JP WO2023210740 A5 JPWO2023210740 A5 JP WO2023210740A5 JP 2024518024 A JP2024518024 A JP 2024518024A JP 2024518024 A JP2024518024 A JP 2024518024A JP WO2023210740 A5 JPWO2023210740 A5 JP WO2023210740A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- disease
- pharmaceutically acceptable
- acceptable salt
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022075222 | 2022-04-28 | ||
| PCT/JP2023/016628 WO2023210740A1 (ja) | 2022-04-28 | 2023-04-27 | ベンゾチオフェン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023210740A1 JPWO2023210740A1 (https=) | 2023-11-02 |
| JPWO2023210740A5 true JPWO2023210740A5 (https=) | 2026-04-27 |
Family
ID=88518799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518024A Pending JPWO2023210740A1 (https=) | 2022-04-28 | 2023-04-27 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250296939A1 (https=) |
| EP (1) | EP4516792A4 (https=) |
| JP (1) | JPWO2023210740A1 (https=) |
| TW (1) | TW202345792A (https=) |
| WO (1) | WO2023210740A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI842738A7 (fi) * | 1983-07-14 | 1985-01-15 | Syntex Inc | Aroyylibentsofuraani- ja bentsotiofeenietikka- ja propionihapot. |
| CA2856306A1 (en) | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Selective kinase inhibitors |
| KR102301867B1 (ko) | 2013-12-18 | 2021-09-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| AU2015266453C1 (en) | 2014-05-30 | 2018-09-13 | Shanghai Emerald Wellcares Pharmaceutical Co., Ltd | Alk kinase inhibitor, and preparation method and use thereof |
| EP3766878B1 (en) * | 2015-06-15 | 2022-03-16 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| SI3782996T1 (sl) * | 2015-06-15 | 2024-06-28 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulatorji |
| JP2020502136A (ja) * | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのビスアリールアミド |
| JP2020502123A (ja) * | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのビスアリール複素環 |
| US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
| CA3044773A1 (en) * | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activators |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| CN110418791B (zh) | 2017-04-28 | 2022-07-01 | 四川科伦博泰生物医药股份有限公司 | 包含苯并二氮䓬类化合物的注射用组合物及其制备方法 |
| GB2575675A (en) | 2018-07-19 | 2020-01-22 | Imperial College Sci Tech & Medicine | A device |
| JP7602469B2 (ja) * | 2019-02-15 | 2024-12-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン |
| MX2021014680A (es) * | 2019-05-31 | 2022-04-06 | Ube Corp | Derivado de benzotriazol. |
| CN114080389B (zh) * | 2019-07-03 | 2024-08-30 | 千寿制药株式会社 | Nrf2活性化化合物 |
-
2023
- 2023-04-27 US US18/860,853 patent/US20250296939A1/en active Pending
- 2023-04-27 JP JP2024518024A patent/JPWO2023210740A1/ja active Pending
- 2023-04-27 WO PCT/JP2023/016628 patent/WO2023210740A1/ja not_active Ceased
- 2023-04-27 EP EP23796476.2A patent/EP4516792A4/en active Pending
- 2023-04-27 TW TW112115866A patent/TW202345792A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7591066B2 (ja) | Ｌｐａ受容体アンタゴニスト及びそれらの使用 | |
| US20250304554A1 (en) | Lpa receptor antagonists and uses thereof | |
| CN106061978B (zh) | 用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶 | |
| JP5735986B2 (ja) | 新規抗マラリア剤 | |
| CA2513081C (en) | Pyrrolopyridazine derivatives | |
| MD4081511T2 (ro) | Derivați carboxilici cu proprietăți antiinflamatorii | |
| CN106795147B (zh) | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 | |
| JP2019516744A (ja) | ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| CN112707854B (zh) | 吡咯酰胺类化合物及其用途 | |
| TW201033194A (en) | Hetero ring derivative | |
| US10023534B2 (en) | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | |
| JP7088933B2 (ja) | Ｎｒｆ２活性化物質 | |
| JP2020503332A5 (https=) | ||
| JP2022504730A (ja) | 脂肪酸合成酵素（ｆａｓｎ）の阻害 | |
| US20150031682A1 (en) | Anti-malarial agents | |
| US20160304486A1 (en) | Indoline compounds as aldosterone synthase inhibitors | |
| RU2746001C2 (ru) | Производные 3-(6-хлор-3-оксо-3,4-дигидро-(2h)-1,4-бензоксазин-4-ил)пропионовой кислоты и их применение в качестве ингибиторов kmo | |
| JP2020522461A (ja) | 抗菌剤として有用な複素環式化合物及びその生成方法 | |
| JPWO2023210740A5 (https=) | ||
| JP7048601B2 (ja) | ｍＧｌｕＲ７調節疾患、障害、または病状を処置するためのｍＧｌｕＲ７アゴニスト化合物 | |
| JPWO2023210741A5 (https=) | ||
| RU2024129723A (ru) | Соединение бензотриазола | |
| US12083092B2 (en) | Antiviral 1,3-di-oxo-indene compounds | |
| JP2009509927A5 (https=) | ||
| CN114671856A (zh) | 多取代的尿嘧啶衍生物及其用途 |